Research map: Envafolimab – novel anti-PD-1/PD-L1 antibody in cancer treatment

Back to the article

Papers in this map

  1. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency · Dung Thi Le · 2015 · 9599 citations · Cited by this paper
  2. A review of soluble mediator and cytokine networks linking combination immunotherapy, tumor microenvironment remodeling and skeletal muscle dysfunction · 2026 · Related
  3. Cancer statistics, 2024 · Rebecca L. Siegel · 2024 · 9523 citations · Cited by this paper
  4. GFI1 as a novel regulator of γδ T cell development and the IL-17/IFN-γ lineage commitment · 2026 · Related
  5. T cell exhaustion · E. John Wherry · 2011 · 4141 citations · Cited by this paper
  6. HIF-1α-centered metabolic reprogramming in osteoarthritis: cell type-specific effects and intercellular crosstalk among chondrocytes, BMSCs, and macrophages · 2026 · Related
  7. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade · Nicholas McGranahan · 2016 · 3184 citations · Cited by this paper
  8. Acquired immune-mediated thrombotic thrombocytopenic purpura with severe cholestatic liver injury and reversible acute kidney injury after ivonescimab-containing chemoimmunotherapy: a case report and literature review · 2026 · Related
  9. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study · Michael James Overman · 2017 · 2892 citations · Cited by this paper
  10. Lipoprotein (a) fuels EV71 replication by activating p38 MAPK-autophagy axis · 2026 · Related
  11. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation · Muhammad Zaeem Noman · 2014 · 2214 citations · Cited by this paper
  12. Delivery platforms for in vivo CAR-T engineering · 2026 · Related
  13. Immunotherapy in colorectal cancer: rationale, challenges and potential · Karuna Ganesh · 2019 · 2093 citations · Cited by this paper
  14. Integrated plasma proteomics identifies HLA-G and osteopontin as circulating biomarkers of resistance to PD-1 inhibitor plus chemotherapy in choriocarcinoma · 2026 · Related
  15. A History of Cancer Chemotherapy · Vincent T. DeVita · 2008 · 1982 citations · Cited by this paper
  16. Contribution of monocyte subpopulations to the pathogenesis and therapy outcome of type 1 diabetes management in pediatric patients · 2026 · Related
  17. Defining ‘T cell exhaustion’ · Christian U. Blank · 2019 · 1675 citations · Cited by this paper
  18. Germline based SARS-CoV-2 specific B cell repertoire motif identified with novel sequence based bioinformatic pipeline · 2026 · Related
  19. New approaches and procedures for cancer treatment: Current perspectives · Dejene Tolossa Debela · 2021 · 1580 citations · Cited by this paper
  20. The current state and future of T-cell exhaustion research · 2023 · Related
  21. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape · Xianjie Jiang · 2019 · 1518 citations · Cited by this paper
  22. Mechanisms Controlling PD-L1 Expression in Cancer · Jong‐Ho Cha · 2019 · 1098 citations · Cited by this paper
  23. Natural killer cells in cancer biology and therapy · Song‐Yang Wu · 2020 · 897 citations · Cited by this paper
  24. Regulatory mechanisms of PD-1/PD-L1 in cancers · Xin Lin · 2024 · 775 citations · Cited by this paper
  25. Immunogenic cell death in cancer therapy: Present and emerging inducers · Jingyi Zhou · 2019 · 739 citations · Cited by this paper
  26. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy · Pengfei Zhao · 2019 · 727 citations · Cited by this paper
  27. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells · Hiro Sato · 2017 · 716 citations · Cited by this paper
  28. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade · Wassim M. Abida · 2018 · 685 citations · Cited by this paper
  29. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations · Yongshuai Jiang · 2019 · 656 citations · Cited by this paper
  30. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy · Jing Gao · 2022 · 563 citations · Cited by this paper
  31. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project · Diana M. Merino · 2020 · 517 citations · Cited by this paper
  32. Chemotherapy: a double-edged sword in cancer treatment · Nafiseh Behranvand · 2021 · 401 citations · Cited by this paper
  33. Recognition of Tumors by the Innate Immune System and Natural Killer Cells · Assaf Marcus · 2014 · 392 citations · Cited by this paper
  34. Tumor-Associated Macrophages: Implications in Cancer Immunotherapy · Amy J. Petty · 2017 · 375 citations · Cited by this paper
  35. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy · Weiqin Jiang · 2021 · 351 citations · Cited by this paper
  36. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies · Nisha Kumari · 2022 · 337 citations · Cited by this paper
  37. Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy · Kristina Hoot Young · 2016 · 323 citations · Cited by this paper
  38. Regulatory T cells (Treg) and Their Roles in Immune System with Respect to Immunopathological Disorders · Kateřina Kondělková · 2010 · 281 citations · Cited by this paper
  39. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications · Claudio Luchini · 2020 · 257 citations · Cited by this paper

Source: OpenAlex (CC0)